People: Monsanto Co (MON.N)

MON.N on New York Stock Exchange

113.55USD
4:01pm EDT
Price Change (% chg)

$0.92 (+0.82%)
Prev Close
$112.63
Open
$113.00
Day's High
$113.85
Day's Low
$112.28
Volume
663,617
Avg. Vol
966,663
52-wk High
$128.77
52-wk Low
$102.88

Search Stocks

Poste, George 

Brief Biography

Dr. George H. Poste, Ph.D., D.V.M., is Independent Director of Monsanto Co. Chief Executive of Health Technology Networks, a consulting group specializing in the application of genomics technologies and computing in healthcare, since 1999; Chief Scientist, Complex Adaptive Systems Initiative, since 2009; Director of the Biodesign Institute, a combination of research groups at Arizona State University, 2003-2009; Chief Science and Technology Officer and Director, SmithKline Beecham, 1992-1999. Public Company Directorships in the Last Five Years: Exelixis, Inc.; Orchid Cellmark, Inc. (former). Dr. Poste is a scientist who has had extensive experience advising and leading research teams in both corporate and academic settings. He is a leader in synthetic biology and healthcare informatics, linking university research projects and collaborations. His roles as chief scientist leading research at a large university, and formerly as chief technology officer of a multi-national company, provide him valuable insight into the biotechnology industry and enable him to provide expert guidance, as chair of our science and technology committee, to our management and board as we develop and implement our technology strategies and research collaborations. In addition, his former roles on scientific advisory boards to the Federal government have also given him extensive experience related to risk management and regulatory and policy matters. His service as a director of other public companies, and as a member of the governance committee and chair of the research committees of other public companies, also bring valuable perspectives to our board.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Hugh Grant

12,574,200

Brett Begemann

3,895,170

Pierre Courduroux

3,143,040

Robert Fraley

3,901,680

David Snively

3,148,730

Steven Mizell

--
As Of 30 Aug 2013
Search Stocks